2019-03-25
Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor
Publication
Publication
Cancer Investigation , Volume 37 - Issue 3 p. 156- 162
Mannose-binding lectin (MBL) - deficient patients who undergo chemotherapy for a solid tumor might have an increased risk developing febrile neutropenia (FN). We investigated in a prospective cohort study relations between MBL-serum levels and polymorphisms in MBL promotor genotypes (550H/L and 221X/Y) on incidence and severity of FN. Risk of FN was 17.9% in MBL-deficient and 22.5% in MBL-sufficient patients (RR ¼ 0.796, p ¼ 0.45). Median MBL serum levels at baseline were respectively 1.39 mg/mL and 1.09 mg/mL (p ¼ 0.92) in patients with and without FN. In conclusion, serum MBL and MBL genotypes (550H/L and 221X/Y) do not determine the risk for developing FN.
| Additional Metadata | |
|---|---|
| , , , , | |
| doi.org/10.1080/07357907.2019.1582660, hdl.handle.net/1765/116827 | |
| VSNU Open Access deal | |
| Cancer Investigation | |
| Organisation | Department of Medical Oncology |
|
Epskamp, C., Goudzwaard, J., Fiets, E., Zuetenhorst, J.M., Polee, M., van de Geijn, G.-J., … Hamberg, P. (2019). Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor. Cancer Investigation, 37(3), 156–162. doi:10.1080/07357907.2019.1582660 |
|